Skip to content


Oslo, Norway, 23 April 2015: Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialization of novel targeted therapeutics in haematology and oncology, announces that results of its Phase 1 clinical study of Betalutin™ in patients with relapsed CD37+ Non-Hodgkin Lymphoma (NHL) will be presented at the International Conference on Malignant Lymphoma (13-ICML) that will take place on June 17 -20 in Lugano, Switzerland. Data and analysis will be presented in a poster on June 18 and 19 by Dr Arne Kolstad, Senior Consultant in Medical Oncology and Radiation Therapy at the Oslo University Hospital, Norwegian Radium Hospital, the study’s Principal Investigator.

Betalutin™ comprises a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). Preliminary data from the study, presented at the American Society of Hematology Conference in December 2014, demonstrated Betalutin™’s promising efficacy and safety profile. Based on these results, Nordic Nanovector is advancing the clinical development of Betalutin™ in both relapsed/refractory CD37+ follicular lymphoma and relapsed/refractory CD37+ diffuse large B-cell lymphoma using proceeds from its recently complete initial public offering and previous fundraisings. Betalutin™ has orphan-drug designation for treatment of follicular lymphoma in the US and Europe.

For further information, please contact:
Luigi Costa, CEO, or Tone Kvåle, CFO
Tel: +47 22 18 33 01

Media Enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948

Knut Ekern (Gambit Hill & Knowlton)
Tel: +47 22 04 82 00

About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and commercialization of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin™, the first in a new class of Antibody-Radio-Conjugates (ARCs), designed to improve upon and complement current options for the treatment of Non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.

Betalutin™ comprises a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). It has shown promising efficacy and a favourable safety profile in Phase 1 studies in a difficult-to-treat NHL patient population. Betalutin™ is fast advancing through clinical development for the treatment of major types of NHL with first approval anticipated in 2018.

Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialization of Betalutin™ in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat a number of select cancer indications.

Further information about the Company can be found at

Forward-looking statements
This announcement may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of Nordic Nanovector’s strategy and its ability to further grow, risks associated with the development and/or approval of Nordic Nanovector’s products candidates, ongoing clinical trials and expected trial results, the ability to commercialise BetalutinTM, technology changes and new products in Nordic Nanovector’s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Source: Nordic Nanovector